Richard Burr: “The most significant part is for the undergraduates who were not subsidized, they would go from 6.8 to 3.6.”

What does it mean for a small company when FDA misses these goals, and what does it mean to patients?

I always like to bring things back to the present because I have a tremendous amount of respect for all four of you.

I went through a litany in my opening statements of the deficiencies in what FDA committed to and what they missed.

Nobody has worked harder on this issue, I think, on the Hill than I have.